Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felipe C Geyer

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 4, 2020
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarityFresia Pareja, Edaise M da Silva, Denise Frosina, et al.
Molecular Cancer Therapeutics|April 21, 2021
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing MalignanciesQing Sheng, Joseph A D'Alessio, Daniel L Menezes, et al.
Nature Communications|May 10, 2018
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomasFelipe C Geyer, Anqi Li, Anastasios D Papanastasiou, et al.
Nature Genetics|June 3, 2020
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapyAlejandro Jiménez-Sánchez, Paulina Cybulska, Katherine LaVigne Mager, et al.
Cancer Research|December 4, 2016
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear PolaritySarah Chiang, Britta Weigelt, Huei-Chi Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2017
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast CancerXiaowei Xu, Carmine De Angelis, Kathleen A Burke, et al.
Nature Communications|September 1, 2018
Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumorsFresia Pareja, Alissa H Brandes, Thais Basili, et al.
NPJ Breast Cancer|August 21, 2019
Homologous recombination DNA repair defects in <i>PALB2-</i>associated breast cancersAnqi Li, Felipe C Geyer, Pedro Blecua, et al.
NPJ Breast Cancer|November 23, 2019
Erratum: Publisher Correction: Homologous recombination DNA repair defects in <i>PALB2</i>-associated breast cancersAnqi Li, Felipe C Geyer, Pedro Blecua, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2009
PPM1D is a potential therapeutic target in ovarian clear cell carcinomasDavid S P Tan, Maryou B K Lambros, Sydonia Rayter, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 4, 2020
Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarityFresia Pareja, Edaise M da Silva, Denise Frosina, et al.
Molecular Cancer Therapeutics|April 21, 2021
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing MalignanciesQing Sheng, Joseph A D'Alessio, Daniel L Menezes, et al.
Nature Communications|May 10, 2018
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomasFelipe C Geyer, Anqi Li, Anastasios D Papanastasiou, et al.
Nature Genetics|June 3, 2020
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapyAlejandro Jiménez-Sánchez, Paulina Cybulska, Katherine LaVigne Mager, et al.
Cancer Research|December 4, 2016
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear PolaritySarah Chiang, Britta Weigelt, Huei-Chi Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2017
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast CancerXiaowei Xu, Carmine De Angelis, Kathleen A Burke, et al.
Nature Communications|September 1, 2018
Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumorsFresia Pareja, Alissa H Brandes, Thais Basili, et al.
NPJ Breast Cancer|August 21, 2019
Homologous recombination DNA repair defects in <i>PALB2-</i>associated breast cancersAnqi Li, Felipe C Geyer, Pedro Blecua, et al.
NPJ Breast Cancer|November 23, 2019
Erratum: Publisher Correction: Homologous recombination DNA repair defects in <i>PALB2</i>-associated breast cancersAnqi Li, Felipe C Geyer, Pedro Blecua, et al.
Pageof 9